- Original article
- Open Access
Efficacy and safety of intrapleural cisplatin versus silver nitrate in treatment of malignant pleural effusion
Egyptian Journal of Bronchology volume 12, pages 98–104 (2018)
Malignant pleural effusion is a frequent problem. Pleurodesis is performed to prevent its recurrence. New, effective, and safe sclerosing agents are needed.
The aim of this was to compare efficacy and safety of silver nitrate solution 0.5% versus cisplatin in achievement of pleurodesis in malignant pleural effusion.
Patients and methods
Prospective randomized single-blinded clinical trial performed at Chest, Clinical Oncology and Nuclear Medicine and Pathology Departments, Mansoura University, from February 2016 to March 2017. A total of 60 patients (26 male and 34 female) with malignant pleural effusion were divided into two groups: first group included 30 patients who were managed with silver nitrate pleurodesis, and second group included 30 patients who were managed by intrapleural cisplatin injection. The success rate of pleurodesis was considered if there was no clinical or radiological recurrence of effusion for 1 month after intervention.
There were significant improvements in cough, chest pain, and dyspnea in the two groups after 1 month versus that before pleurodesis. The success rate of pleurodesis in silver nitrate group was 90 versus 76.7% in cisplatin group, without significant difference (P=0.166). Chest pain was reported in 26.7% in silver nitrate group and 13.3% in cisplatin group, and fever was reported in 33.3% in silver nitrate group and 20.0% in cisplatin group. Recurrence was reported in 10% in silver nitrate group and in 23.3% in cisplatin group.
Silver nitrate and cisplatin were nearly equally effective, safe, and less expensive agents in achievement of pleurodesis in patients with malignant effusion with high success rate and low complications.
Rafei H, Jabak S, Mina A, Tfayli A. Pleurodesis in malignant pleural effusions: outcome and predictors of success. Integr Cancer Sci Therap 2015; 2:216–221.
Sonoda A, Jeudy J, White CS, Kligerman SJ, Nitta N, Lempel J, Frazier AA. Pleurodesis: indications and radiologic appearance. Jpn J Radiol 2015; 33:241–245.
Janssen JP, Collier G, Astoul P, Tassi GF, Noppen M, Rodriguez-Panadero F, et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 2007; 369:1535–1539.
Mourad IA, Sherif AM, Aziz A, Saber NM, Fouad FA. Pleurodesis as a palliative treatment of advanced lung cancer with malignant pleural effusion. J Egypt Natl Cancer Inst 2004; 16:188–194.
Light R. Effusion due to malignancy. Textbook of pleural diseases. 6th ed. Wolters Kluwer: Lippincott Williams & Wilkins; 2013. 10:153–189.
Zhao WZ, Wang K, Li W, Zhang XL. Clinical research on recombinant human Ad-p53 injection combined with cisplatin in treatment of malignant pleural effusion induced by lung cancer. Ai Zheng 2009; 28:1324–1327.
Belfiore G, Moggio G, Tedeschi E, Greco M, Cioffi R, Cincotti F, et al. CT-guided radiofrequency ablation: a potential complementary therapy for patients with unresectable primary lung cancer – a preliminary report of 33 patients. Am J Roentgenol 2004; 183:1003–1011.
Melzack R. The short-form McGill Pain Questionnaire. Pain 1987; 30:191–197.
Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93:580–586.
Mironov O, Ishill NM, Mironov S, Vargas HA, Zheng J, Moskowitz C, et al. Pleural effusion detected at CT prior to primary cytoreduction for stage III or IV ovarian carcinoma: effect on survival. Radiology 2011; 258: 776–784.
Seto T, Ushijima S, Yamamoto H, Ito K, Araki J, Inoue Y, et al. Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial. Br J Cancer 2006; 95:717–721.
Lee WJ, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, et al. Chemical pleurodesis for the management of refractory hepatic hydrothorax in patients with decompensated liver cirrhosis. Korean J Hepatol 2011; 17:292–298.
Dresler CM, Olak J, Herndon JE, Richards WG, Scalzetti E, Fleishman SB, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127:909–915.
Davies HE, Lee YCG, Davies RJO. Pleurodesis for malignant pleural effusion: talc, toxicity and where next? Thorax 2008; 63:572–574.
Menna C, Andreetti C, Ibrahim M, Maurizi G, Poggi C, Barile R, et al. The effect of silver nitrate pleurodesis after a failed thoracoscopic talc poudrage. Biomed Res Int 2013; 2013:1–5.
Saffran L, Ost DE, Fein AM, Schiff MJ. Outpatient pleurodesis of malignant pleural effusion using small bore pigtail catheter. Chest 2000; 118: 417–421.
Parulekar W, Di primio G, Matzinger F, Dennie C, Bociek G. Use of small bore versus large bore chest tube for treatment of malignant pleural effusion. Chest 2001; 120:19–25.
Caglayan B, Torun L, Turan D, Fidan A, Gemici C, Sarac G, et al. Efficacy of iodopovidone pleurodesis and comparison of small bore catheter versus lage bore chest tube. Ann Surg Oncol 2008; 15:2594–2599.
Dey A, Bhuniya S, Datta Chaudhuri A, Pandit S, Saha-Dutta Chowdhury M, Sengupta A, et al. Iodopovidone pleurodesis: experience of a tertiary hospital in Kolkata. Singapore Med J 2010; 51:163–165.
Paschoalini M, Da S, Vargas FS, Marchi E, Pereira JR, Jatene FB, Antonangelo L. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions. Chest 2005; 128:684–689.
Terra RM, Kim SY, Pego-Fernandes PM, Teixeira LR, Vargas FS, Jatene FB. Is silver nitrate pleurodesis for patients with malignant pleural effusion feasible and safe when performed in an outpatient setting? Ann Surg Oncol 2011; 18:1145–1150.
Rusch VW, Figlin R, Godwin D, Piantadosi S. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a lung cancer study group trial. J Clin Oncol 1991; 9:313–319.
Tohda Y, Iwanaga T, Takada M, Yana T, Kawahara M, Negoro S, et al. Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer. Chemotherapy 1999; 45:197–204.
Figlin R, Mendoza E, Piantadosi S, Rusch V. Intrapleural chemotherapy without pleurodesis for malignant pleural effusions: LCSG Trial 861. Chest 1994; 106(suppl):363s–366s.
Kim KW, Park SY, Kim MS, Kim SC, Lee EH, Shin SY, et al. Intrapleural chemotherapy with cisplatin and cytarabine in the management of malignant pleural effusion. Cancer Res Treat 2004; 36:68–71.
Vargas FS, Antonangelo L, Capelozzi VL, Vaz MA, Genofre EH, Marchi E, Teixeira LR. Lung damage in experimental pleurodesis induced by silver nitrate or talc: 1-year follow-up. Chest 2002; 122:2122–2126.
Mohsen TA, Abou Zeid AA, Meshref M, Haj-Yahi S, et al. Local iodine pleurodesis versus thoracoscopic talc insufflation in recurrent malignant pleural effusion: a prospective randomized control trial. Eur J Cardiothorac Surg 2011; 40:282–286.
El-Morsy AS, El-Desoky ME, Fouda MA, Mansour AE, E l-Hadidy TA. Comparative study of povidone iodine and viscum as pleurodesis agents via large bore chest tube aftermedical thoracoscopy and small bore catheter in malignant pleural effusion. Egypt J Chest Dis Tuberc 2012; 61:112–119.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as the author is credited and the new creations are licensed under the identical terms.
About this article
Cite this article
El Badrawy, M.K., Ali, R.EM., Hewidy, A.A. et al. Efficacy and safety of intrapleural cisplatin versus silver nitrate in treatment of malignant pleural effusion. Egypt J Bronchol 12, 98–104 (2018). https://doi.org/10.4103/ejb.ejb_39_17
- malignant effusion
- silver nitrate